{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:43:24Z","timestamp":1765233804978,"version":"3.41.2"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Thalidomide\u2010containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma. As thalidomide toxicity is dose\u2010dependent, identifying the most appropriate dose for each patient is essential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to investigate the effects of a thalidomide dose step\u2010up strategy on treatment response and progression\u2010free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>This prospective observational study included 93 patients with newly diagnosed multiple myeloma (NDMM) who received bortezomib, thalidomide, and dexamethasone (VTD). The present study assessed the incidence of thalidomide dose reduction and discontinuation, the overall dose intensity, and their effects on therapeutic efficacy. Furthermore, this study used Cox proportional hazard models to analyze the factors contributing to thalidomide intolerability. The results showed the overall response rates in all patients and the evaluable patients were 78.5% and 98.7%, respectively. The median PFS in the study cohort was not reached. The most common thalidomide\u2010related AEs were constipation (32.3%) and skin rash (23.7%), resulting in dose reduction and discontinuation rates of 22.6% and 21.5%, respectively. The responders had a significantly higher average thalidomide dose intensity than the nonresponders (88.6% vs. 42.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The thalidomide dose step\u2010up approach is a viable option for patients with NDMM receiving VTD induction therapy with satisfactory efficacy and tolerability. However, thalidomide intolerance may lead to dose reduction or discontinuation due to unpredictable AEs, leading to lower dose intensity and potentially inferior treatment outcomes. In addition to a dose step\u2010up strategy, optimal supportive care is critical for patients with multiple myeloma receiving VTD induction therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.2102","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T10:45:17Z","timestamp":1716374717000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose <scp>step\u2010up<\/scp> strategy in patients with newly diagnosed multiple myeloma: A prospective observational study"],"prefix":"10.1002","volume":"7","author":[{"given":"Po\u2010Wei","family":"Liao","sequence":"first","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh\u2010Ju","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine Chung Shan Medical University Hospital  Taichung Taiwan"},{"name":"School of Medicine Chung Shan Medical University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung\u2010Chih","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine College of Medicine, National Chung Hsing University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin\u2010Chen","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine College of Medicine, National Chung Hsing University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Hsuan","family":"Shih","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine College of Medicine, National Chung Hsing University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-0368","authenticated-orcid":false,"given":"Chieh\u2010Lin Jerry","family":"Teng","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital  Taichung Taiwan"},{"name":"School of Medicine Chung Shan Medical University  Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine College of Medicine, National Chung Hsing University  Taichung Taiwan"},{"name":"Department of Life Science Tunghai University  Taichung Taiwan"},{"name":"Ph.D. Program in Translational Medicine National Chung Hsing University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_10_3_1","unstructured":"SEER Stat Fact Sheets: Myeloma.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03858-w"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020130"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05914.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00223-1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp079"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002593"},{"issue":"3","key":"e_1_2_10_17_1","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial IM","year":"2003","journal-title":"J Support Oncol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0629-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36695"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1506-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0399-y"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.2102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T14:38:03Z","timestamp":1716907083000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.2102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/cnr2.2102"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.2102","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2102"}}